Nitin Roper MD

Physician-Scientist Early Investigator and Thoracic Oncologist at the NCI. All views and tweets are my own and do not reflect those of the NIH or government.

[Nitin Roper MD @nitinroper]

@MontessaLee Hi Montessa - I am a lung cancer researcher at the NCI in Bethesda, MD. Would you be willing to assist as an advocate for a career development award grant in SCLC? If so, please email me at [email protected]. Many thanks for your consideration.

[Nitin Roper MD @nitinroper]

In science we depend on @FedEx to safely and quickly move reagents between labs (even during the pandemic). We have yet to receive a valuable, overnight package after 3 days. Can @FedExHelp provide some help?

[Nitin Roper MD @nitinroper]

New postdoctoral position is available in my laboratory to study neuroendocrine tumor immunology using novel patient-derived organoids and translational studies in upcoming clinical trials with @JaydiDelRivero https://t.co/islLfS9Kln

[Nitin Roper MD @nitinroper]

Excited to attend the upcoming Forbeck meeting "Neuroendocrine Cell Fate in Development and Cancer" and learn from the top experts in the field

[Nitin Roper MD @nitinroper]

In our new paper @NatureComms we have uncovered mechanistic insights into why only a small minority of patients with relapsed small cell lung cancer respond to immunotherapy. https://t.co/KhuYcdgJDx @NCIResearchCtr @theNCI

[Nitin Roper MD @nitinroper]

@chulkimMD @drgandara @drgandara @chulkimMD 2 explanations - 1. MET amp is a subclonal resistance mechanism (spatial heterogeneity) and 2. MET amp appears at first or second osi progression (temporal heterogeneity). Pts with longer response to osi did not evidence of MET amp

[Nitin Roper MD @nitinroper]

@theNCI @NCIResearchCtr

[Nitin Roper MD @nitinroper]

Check out our paper taking a deep dive into EGFR mutant lung cancer resistance mechanisms in very first issue of @CellRepMed. This was translational research at its best, a collaborative effort of medical/radiation oncology, surgery and bioinformatics. https://t.co/R21RyQ47KX

[AL Brown @annaleighbrown2]

Whoo!! Our paper using multi-region phylogeny to explore the resistance mechanisms of EGFR mutant lung cancer is out! I'm really proud of the work we put into this and it's great to see it out in the world and in the very first issue of @CellRepMed
https://t.co/EtpC3qTcWy

[JAMA Internal Medicine @JAMAInternalMed]

Does industry input on trial design affect outcomes? http://t.co/xqbgfRFP3p

[Nitin Roper MD @nitinroper]

MT @RamanKhannaUCSF about our @JAMAInternalMed paper. Surrogate outcomes: That’s not why we play the game http://t.co/CnHbT5N1or

[Nitin Roper MD @nitinroper]

Editorial about our paper: "It’s Not Just About the Money, Money, Money." http://t.co/KHwCRt9dsz @JAMAInternalMed @jsross119

[Nitin Roper MD @nitinroper]

Our paper @JAMAInternalMed Trials with industry collaboration, not industry funding, more likely to be positive http://t.co/ZtAiDy4AVK

[Nitin Roper MD @nitinroper]

From @NewYorker: the power of genetic sequencing to identify previously unknown medical conditions. http://t.co/wURlxY8YFc

[Nitin Roper MD @nitinroper]

Percentage of precision cancer medicine trials in the U.S. has increased from 3% in 2006 to 16% in 2013. #ASCO14

[Jennifer Ersek @JLErsek]

Percentage of #precisionmedicine trials in the U.S. has increased from 3% in 2006 to 16% in 2013. Roper et al. Abstract number 1547 #LCI

[Nitin Roper MD @nitinroper]

Future of precision cancer medicine will be large clinical registries such as Cancer LinQ, not randomized trials. - Dr. Schilsky #ASCO14

[Nitin Roper MD @nitinroper]

How Germany, unlike the U.S., creates a competitive market for prescription drugs. http://t.co/B0A0CzDtME

[Joseph Ross @jsross119]

FDA to Put Almost $38 Million Behind Effort to Improve Clinical Trials http://t.co/0VB2eHAy8U

[Ryan Nipp, MD, MPH, MBA, FASCO @RyanNipp]

Progress Against GI Cancer During @ASCO First 50 Years. http://t.co/QjKQPrbtyx #cancer #pancreaticcancer #coloncancer